EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma

被引：0
|
作者：
Maria Colombino
Panagiotis Paliogiannis
Antonio Cossu
Davide Adriano Santeufemia
Maria Cristina Sini
Milena Casula
Grazia Palomba
Antonella Manca
Marina Pisano
Valentina Doneddu
Giuseppe Palmieri
机构：
[1] Institute Biomolecular Chemistry,Unit of Cancer Genetics
[2] CNR,Department of Medical, Surgical, and Experimental Sciences
[3] University of Sassari,undefined
[4] Medical Oncology Unit,undefined
[5] Civil Hospital,undefined
来源：
BMC Pulmonary Medicine | / 19卷
关键词：
Lung cancer; Adenocarcinoma; Targeted therapies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
    Mak, Kimberley S.
    Gainor, Justin F.
    Niemierko, Andrzej
    Oh, Kevin S.
    Willers, Henning
    Choi, Noah C.
    Loeffler, Jay S.
    Sequist, Lecia V.
    Shaw, Alice T.
    Shih, Helen A.
    NEURO-ONCOLOGY, 2015, 17 (02) : 296 - 302
  • [32] EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
    Chalela, Roberto
    Gonzalez-Garcia, Jose Gregorio
    Khilzi, Karys
    Curull, Victor
    Sanchez-Font, Albert
    Longaron, Raquel
    Rodrigo-Calvo, Maria Teresa
    Martin-Ontiyuelo, Clara
    Gea, Joaquim
    Bellosillo, Beatriz
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [33] EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations
    Chiosea, Simion
    Shuai, Yongli
    Cieply, Kathleen
    Nikiforova, Marina N.
    Dacic, Sanja
    HUMAN PATHOLOGY, 2010, 41 (08) : 1053 - 1060
  • [34] Lung Adenocarcinoma in Young Adults: EGFR/KRAS/ALK Mutation Status and Clinicopathological Features in 64 Patients under Age 40
    Dogan, S.
    Jhanwar, S. C.
    Ladanyi, M.
    Zakowski, M. F.
    MODERN PATHOLOGY, 2011, 24 : 407A - 408A
  • [35] Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
    Wu, Shafei
    Wang, Jinghui
    Zhou, Lijuan
    Su, Dan
    Liu, Yuanyuan
    Liang, Xiaolong
    Zhang, Shucai
    Zeng, Xuan
    THORACIC CANCER, 2015, 6 (04) : 413 - 420
  • [36] Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
    Kim, Ho Cheol
    Kang, Yeh Rim
    Ji, Wonjun
    Kim, Yeon Joo
    Yoon, Shinkyo
    Lee, Jae Cheol
    Choi, Chang-Min
    ONCOTARGETS AND THERAPY, 2019, 12 : 6045 - 6052
  • [37] Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
    Yashima, Hideaki
    Shimizu, Kimihiro
    Araki, Takuya
    Aomori, Tohru
    Ohtaki, Yoichi
    Nagashima, Toshiteru
    Enokida, Yasuaki
    Atsumi, Jun
    Nakamura, Tomonori
    Takeyoshi, Izumi
    Yamamoto, Koujirou
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 714 - 718
  • [38] CONCURRENT TARGETABLE GENETIC DRIVER ALTERATIONS IN KRAS-MUTANT LUNG ADENOCARCINOMA
    Paul, D.
    Rafael, O. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 60 : E15 - E16
  • [39] ALK gene rearrangment in EGFR and KRAS positive lung adenocarcinomas
    Carvalho, L.
    Silva, M. R.
    Alarcao, A.
    Couceiro, P.
    Oliveira, D.
    Sousa, V.
    D'Aguiar, M. J.
    Teixeira, L.
    VIRCHOWS ARCHIV, 2011, 459 : S320 - S320
  • [40] Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
    Ye, Chenyang
    Wang, Ji
    Zheng, Shu
    Chai, Ying
    ONCOTARGETS AND THERAPY, 2016, 9 : 6605 - 6608
12345